NKARTA INC
NKTXNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $1.11 β $3.72
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 71.6M
- Next Earnings
- 2027-03-24
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.73
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.6%
NKARTA INC
NKTXAbout NKARTA INC
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

Nkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026
No cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), or graft-versus-host

Nkarta, Inc. (NKTX) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis Transcript
Nkarta, Inc. ( NKTX ) Discusses Initial NKX019 Clinical Data in Myositis and Systemic Sclerosis November 9, 2026 8:00 AM EST Company Participants Paul Hastings - CEO & Director Shawn Rose - Chief Medical Officer and Head

Nkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR Convergence
In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, to

Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, to

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Nkarta (NASDAQ: NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology's 2026 Convergence meeting in November, including presentations in myosi